Literature DB >> 15785115

Using remifentanil and sufentanil in functional endoscopic sinus surgery to improve surgical conditions.

M Manola1, E De Luca, L Moscillo, A Mastella.   

Abstract

The purpose of the study was to compare three types of general anesthesia for functional endoscopic sinus surgery (ESS) with controlled hypotension measuring the quality of visibility of the surgical field and the blood loss during the operation. Seventy-one patients underwent endoscopic ethmoidectomy bilaterally for nasal polyposis and/or chronic sinusitis. The patients were divided into three groups according to the type of anesthesia they had: group A (sufentanil/sevoflurane), group B (remifentanil/propofol), and group C (fentanyl/isoflurane). The mean estimated blood loss for group A was 117.83 ml, for group B it was 100.5 ml and for group C it was 198.89 ml. The average quality of visibility of the surgical field was 1.57 for group A, 1.3 for group B and 2.79 for group C. The quantity of blood loss (p < 0.01) and the visibility of the surgical field (p < 0.001) demonstrated a difference among the three groups. Remifentanil and sufentanil during functional ESS enable controlled hypotension and a general improvement in surgical conditions. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785115     DOI: 10.1159/000084576

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  15 in total

1.  Comparison of the hemodynamic effects of nitroprusside and remifentanil for controlled hypotension during endoscopic sinus surgery.

Authors:  So Hui Yun; Jeong Hong Kim; Hyun Jung Kim
Journal:  J Anesth       Date:  2014-06-21       Impact factor: 2.078

2.  Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study.

Authors:  A Cardesín; C Pontes; R Rosell; Y Escamilla; J Marco; M J Escobar; M Bernal-Sprekelsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-09-20       Impact factor: 2.503

Review 3.  Quality of surgical field during endoscopic sinus surgery: a systematic literature review of the effect of total intravenous compared to inhalational anesthesia.

Authors:  Elizabeth A Kelly; Suneeta Gollapudy; Matthias L Riess; Harvey J Woehlck; Todd A Loehrl; David M Poetker
Journal:  Int Forum Allergy Rhinol       Date:  2012-12-19       Impact factor: 3.858

Review 4.  Controlled hypotension: a guide to drug choice.

Authors:  Christian-Serge Degoute
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Anaesthesia for direct laryngoscopy with propofol and fentanyl or sufentanil.

Authors:  Uma Srivastava; Abhijeet Rajan Mishra; Siddharth Sharma; Dharmendra Kumar; Aditya Kumar; S Saxena; Imran Khan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2008-11-07

Review 6.  The Role of Anesthetic Selection in Perioperative Bleeding.

Authors:  Koichi Yuki; James A DiNardo; Sophia Koutsogiannaki
Journal:  Biomed Res Int       Date:  2021-05-07       Impact factor: 3.411

7.  Does choice of anesthetics affect intraoperative blood loss?

Authors:  Seonghoon Ko
Journal:  Korean J Anesthesiol       Date:  2012-10-12

8.  Comparison of surgical conditions during propofol or desflurane anesthesia for endoscopic sinus surgery.

Authors:  Kwangrae Cho; Jin Young Lee; Sung Kuk Park; Soon Ho Cheong; Kun Moo Lee; Se Hun Lim; Jeong Han Lee; Myoung-Hun Kim; Hyun-Tae Kim; Jung-Kyu Park
Journal:  Korean J Anesthesiol       Date:  2012-10-12

9.  Volatile anesthetics, not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αIIbβ3.

Authors:  Koichi Yuki; Weiming Bu; Motomu Shimaoka; Roderic Eckenhoff
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

10.  Effects of three different types of anaesthesia on perioperative bleeding control in functional endoscopic sinus surgery.

Authors:  Jarosław Miłoński; Hanna Zielińska-Bliźniewska; Wojciech Golusiński; Joanna Urbaniak; Rafał Sobański; Jurek Olszewski
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-22       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.